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Functional and specific receptors for vasoactive intestinal peptide (VIP) (determined by their capacity to 
bind *zsI-VIP and activate adenylate cyclase) and cyclic AMP-dependent phosphodiesterase activities were 
characterized in enterocytes of human fetal small intestine between 18 and 23 weeks of gestation. Half-max- 
imal stimulation of the cyclase and inhibition of 12sI-VIP binding in membrane preparations were respective- 
ly observed at 1.4 and 5 x lO-‘O M VIP. The peptides structurally related to VIP activated the cyclic AMP 
generating system at pharmacological doses (lo-’ M and above) in the following order of potency: VIP 
> PHI > GRF > secretin. Other peptides or test substances, including GIP, pancreatic glucagon, somatos- 
tatin-14, gastrin, CCK, neurotensin, pancreatic polypeptide, PYY, substance P, histamine and isoproterenol 
are inactive in this system, while the ubiquitous adenylate cyclase activators NaF, forskolin and prostaglan- 
dins were effective. These results, combined with the appearance of intestinal VIP in nerve fibers at 8 weeks 
and with the morphological and enzymatic maturation at 9-12 weeks of the intestinal mucosa, indicate that 
this neuropeptide may regulate either the differentiation or function of enterocytes during the early develop- 
ment of human intestinal mucosa. 
Vasoactive intestinalpeptide Receptor 
1. INTRODUCTION 
Vasoactive intestinal peptide (VIP) was original- 
ly isolated from the small intestine in hogs by Said 
and Mutt [1,2]. VIP might function as a neuro- 
transmitter [3] and affect the behavior of small in- 
testinal epithelial cells by stimulating net fluid and 
electrolyte secretion from enterocytes [4-61. As in 
the case of several other target organs [7,8], the 
biological effects of VIP on the small intestinal 
mucosa are probably mediated via a cyclic AMP- 
dependent mechanism after activation of cell sur- 
face receptors [4,5,9, lo]. 
In human fetuses, VIP was detected as early as 
S-10 weeks of age in the small and large intestine 
[ 11,121, and located in nerve fibers in the myen- 
teric plexus at the 12th week of fetal age [ll]. As 
VIP immunoreactivity during the early develop- 
ment of the human intestine might be of biological 
significance, this study was designed to identify 
Adenylate cyclase Human fetal enterocyte 
and characterize pharmacologically functional 
VIP receptors in enterocytes isolated from fetuses. 
We therefore measured 12’I-VIP binding to mem- 
branes prepared from human fetal enterocytes, 
and compared the abilities of VIP and other pep- 
tides - some of which were related to the structural 
family of VIP and secretin [2,13] - to inhibit 1251- 
VIP binding and to increase adenylate cyclase ac- 
tivity in the same preparation. 
2. EXPERIMENTAL 
2.1. Chemicals 
Highly purified natural porcine VIP, PHI (por- 
cine peptide with N-terminal histidine and C- 
terminal isoleucine amide) and GIP (gastric in- 
hibitory peptide) were purchased from Professor 
V. Mutt (GHI Laboratory, Stockholm, Sweden). 
Crystallized, highly purified porcine glucagon 
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(batch 421306) was from Novo Research Institute 
(Bagsvaerd, Denmark). Synthetic porcine secretin 
and human pancreatic growth hormone releasing 
factor (hpGRF) l-40 were respectively prepared by 
Professor E. Wiinsch (Max Planck Institut fur 
Peptidchemie, Martinsried, FRG) and by Dr J. 
Rivier (Salk Institute, San Diego, CA). Synthetic 
cyclic ovine somatostatin-14, sulfated [Leu]” 
human gastrin I, the C-terminal fragment of 
cholecystokinin (CCK 26-33), bovine substance P 
and neurotensin were from Beckman (Switzerland). 
Synthetic porcine peptide with N-terminal tyrosine 
and C-terminal tyrosine (PYY) was purchased 
from Peninsula Laboratories (Belmont, CA) and 
crystallized bovine pancreatic peptide batch 
103411) was from Bachem (Budendorf, Switzer- 
land). Forskolin, sodium fluoride, isoproterenol 
hydrochloride, histamine dihydrochloride, prosta- 
glandins Er (PGEr), 3-isobutyl-1-methylxanthine 
(IBMX), snake venom (Ophiophagus hannah), 
dithiothreitol, phenylmethylsulfonyl fluoride 
(PMSF), GTP and pure ATP were from Sigma (St. 
Louis, MO). Creatine phosphate (A grade) was 
from Calbiochem and phosphocreatine kinase, 
from Boehringer. [3H]cyclic AMP and Narz51 were 
from the Radiochemical Centre (Amersham, 
England). 
2.2. Human fetal intestine 
Fetal human small intestine was obtained just 
after legal or therapeutically-induced abortions 
with the informed consent of the mothers. Small 
intestines from 4 fetuses (18-23 weeks gestational 
age) were dissected out and divided into five sec- 
tions of equal length. Small bowel segments were 
opened along the lumen with scissors, and washed 
3 times with ice-cold Krebs Ringer phosphate buf- 
fer (pH 7.5) prior to cell isolation. Intestinal 
fragments were then incubated for 15 min at 4°C 
in a solution containing 2.5 mM EDTA and 0.25 M 
NaCl (pH 7.5), as previously described for the 
removal of epithelial cells from rat colon and small 
intestine [9]. Intestinal cells were obtained by gen- 
tle shaking for 10 set twenty times by hand. After 
each period of shaking, the intestine was placed in 
50 ml of fresh medium. The resulting preparation 
was centrifuged (200 xg, 4°C) for 2 min, and 
washed three times at the same speed with 40 ml of 
the EDTA/NaCl solution. Fig. 1 shows the typical 
appearance of the cell preparation containing 
Fig. 1. Morphology of small intestinal epithelial cells in- 
cluded in the intestinal villi in a human abortus at 18 
weeks gestational age. Magnification, x 220. 
enterocytes included in the intestinal villi structures 
[141. 
2.3. Membrane preparation 
Isolated human fetal enterocytes were disrupted 
at 4°C with a Virtis homogenizer (Cenco In- 
struments, Netherlands) in 10 mM Tris-HCl buf- 
fer (pH 7.5) containing 1 mM EDTA, 30 mM 
NaCl, 1 mM dithiothreitol and 5 pM PMSF, using 
five bursts of 5 set each. The broken cell suspen- 
sion was then centrifuged (600 x g, 10 min at 4°C) 
in a Sorvall centrifuge RC-2 (Newton, CT). 
Plasma membrane-enriched particles were ob- 
tained by differential centrifugation (40 000 x g, 20 
min at 4°C). The membranes were stored frozen at 
-80°C for 1 week. 
2.4. Adenylate cyclase assay 
Adenylate cyclase activity was measured by a 
modified version of the method previously des- 
cribed [15]. The standard incubation mixture (final 
vol.: 250,~l) contained 1 mM ATP, 5 mM MgClz, 
the ATP-regenerating system (10 mM creatine 
phosphate and 0.5 mg/ml phosphocreatine kinase), 
0.4 mM IBMX, 4 mg/ml BSA, 1 mM EGTA, 400 
pg/ml bacitracin, 20,~M GTP and test substances 
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in 20 mM Tris-HCl (PH 7.5). The reaction was in- 
itiated by addition of the membrane-bound adeny- 
late cyclase (5-10 pg membrane protein per tube) 
and the mixture incubated at 30°C for 15 min. 
Data are expressed as pmol cyclic AMP produced 
per min and per mg membrane protein. 
2.5, VIP binding assay 
The binding assay was conducted in a standard 
incubation solution containing in a final volume of 
200&‘20 mM Tris-HCl (pH 7.5), 4 mglml BSA, 
800 ag/ml bacitracin and 1251-VIP at about 5 x 
lo-” M. Reactions were started by adding the 
membrane sus~nsion at a concentration of about 
55 ,ug protein per 50 pi. Incubations were per- 
formed at 30°C for 60 min and stopped by filtra- 
tion of a 150 ,ul aliquot through Millipore filters 
(EHWP 0.5 pm). Adsorption of izSI-VIP to filters 
represented 0.7% of the total radioactivity added 
and 8% of the specific binding of 1251-VIP to in- 
testinal membrane, as determined by incubations 
with an excess (lop6 M) of native peptide. Results 
are expressed as the percentage of the radioactivity 
bound in the absence of unlabeled peptide (percent 
of ma~mum). 
2.6, Cyclic AMP-phosphodiesterase preparations 
and assay 
Freshly isolated enterocytes were sonicated in 40 
mM Tris-HCl buffer (pH 8) containing 5 mM 
MgClz and 3.8 mM ,&mercaptoethanol. Phospho- 
diesterase activity [ 161 was measured in 250~1 reac- 
tion mixture containing 22 nM purified [3H]cyclic 
AMP (120000 cpm), 0.029-64pM cyclic AMP, 50 
lug snake venom, 25 pg cell protein, 5 mM MgClz, 
3.8 mM ~-mercaptoethanol in 40 mM Tris-HCl 
buffer (pH 8). The mixture was incubated at 30°C 
for 5 min. The reaction was stopped by addition of 
500 gl anion-exchange resin (AGl-X2, 200-400 
mesh) from Bio-Rad Laboratories, Richmond, 
CA, Data are expressed as pmol cyclic AMP 
hydrolyzed per min and per mg protein. 
3. RESULTS 
Adenylate cyclase activity in plasma membranes 
prepared from human fetal enterocytes was in- 
creased 4-fold by VIP and 2,5 and 20-fold by the 
ubiquitous activators PGEr, sodium fluoride and 
forskolin, respectively (table 1). No effect on 
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Table 1 
Activation by peptides and ubiquitous 
membrane-bound adenylate cyclase in 
enterocytes 
activators of 
human fetal 
Substance Dose n CAMP (pmol/min 
per mg protein) 
None 6 2942 31 
VIP 1o-7 M 6 1130-+ 68 
PGE 4~10-~ M 1 588+ 50 
NaFr 5~10-~ M 6 1430* 100 
Forskolin 4~10-~ M 3 5970* 551 
Values are means 5 SE from experiments performed on 
4 different human fetuses between 18 and 23 weeks 
gestational age. The following peptides or test 
substances were found to be inactive in the same 
preparations: GIP (4x 10e7 M); histamine (10m3 M); 
isoproterenol (2 x lOA M); pancreatic glucagon, 
somatostatin-14, gastrin, CCK, neurotensin, pancreatic 
polypeptide, PYY and substance P (10m6 M) 
adenylate cyclase activity was exerted by the other 
peptides structurally related to VIP (glucagon, 
GIP, somatostatin-14) or by those related to 
neurotensin (pancreatic polypeptide and PYY), or 
gastrin (CCK). Substance P, histamine, or the beta 
adrenergic receptor agonist isoproterenol had no 
action on the membrane-bound adenylate cyclase 
either. We verified that reaction rates were linear 
with time (O-20 min) and with protein concentra- 
tions (4-35 ,ug membrane protein per tube) in the 
absence or presence of low7 M VIP or 5 x 10e3 M 
NaF (fig.2). In the adenylate cyclase assay, the 
4 Ttmc , mmutes Memb~ protein, ~g~tube f 
Fig.2. Effect of time (left) and membrane protein con- 
centration (right) on adenylate cyclase activity in entero- 
cytes isolated from human abortuses. No addition (Cl), 
lo-’ M VIP (e) or 5 x 10m3 M NaF (v). Assay condi- 
tions were specified in section 2. VaIues are means + SE 
from 4 experiments performed on 2 fetuses at 19 and 23 
weeks gestation, respectively. 
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Fig.3. Lineweaver-Burk plots for cyclic AMP-phospho- 
diesterase activity in enterocyte homogenates from an 18 
week-old human fetus. Apparent K, and I’,,,,, values 
were determined by linear regression of the two linear 
components of the plot. The regression coefficients were 
respectively r = 0.993 @<O.Ol) and r = 0.999 
@<O.OOl) for high (left) and low K,,, phosphodiesterase 
(right). Incubation time and protein concentration were 
chosen so as to obtain the steady-state conditions for 
cyclic AMP hydrolysis. Results are means + SE from 3 
experiments performed in duplicate. 
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cyclic AMP phosphodiesterase inhibitor IBMX 
was added to the reaction mixture at a concentra- 
tion of 0.4 mM in order to inhibit the cyclic AMP 
degrading enzymes. Kinetic analysis indicated two 
forms of cyclic AMP phosphodiesterase, one had 
a low K,,, (lkO.04 ,uM, I’,,,,,=13Ort 10 pmol 
cAMP/min per mg protein, as shown in fig.3, 
right) and the other a high Km (35.2+ 8 PM, 
V,,, = 28OOk 270 pmol cAMP/min per mg pro- 
tein, as shown in fig.3, left). 
A significant increase in adenylate cyclase activi- 
ty was detected with a VIP concentration as low 
as lo-l2 M (fig.4, left). Half-maximal and max- 
imal stimulations of this enzyme occurred with 
1.4~ 10-i’ M and 10m9 M VIP, respectively. PHI, 
hpGRF and secretin, three peptides structurally 
related to VIP (table 2), also raised adenylate 
cyclase activity in human fetal intestinal mem- 
branes, with a similar efficacy to that of VIP. 
However, VIP was about IO3 times more potent 
than PHI (Ka = 1.2x lo-’ M), 5.7x lo3 times 
more potent than hpGRF (K, = 8 x lo-’ M) and 
1.2x lo4 times more potent than secretin 
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Fig. 4. Effect of VIP and peptides structurally related to VIP on adenylate cyclase activity (left) or r2’1-VIP binding 
(right) in membrane preparations from human fetal enterocytes. No addition (O), VIP (o), PHI (A), hpGRF (o) or 
secretin (0). Data are means -t SE from 6 experiments performed in 2 fetuses of 19 and 23 weeks gestation, respective- 
ly (left). Individual determinations of membrane-associated r2’I-VIP radioactivity are represented on the right, from 
2 experiments performed on one fetus at 23 weeks gestation. Results are expressed as the percentage of radioactivity 
associated with membranes incubated in the absence of unlabeled peptide (13 pmol 1251-VIP/mg protein). 
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Tabie 2 
Sequence homologies between the peptides of the secretin-VIP family 
January 1985 
pVIP HSDAVFTDNYTRLRKQMAVKKYLNSILN 
pPH1 ~A~G~SDFS~LG~LSA~LE~LI 
hpGRF YADAIFTNS~RKVLGQLSARKLLQDIMSRQQGESNQERGARARL 
psecretin HsDGTmSELSRLRDSARLQRLLQGLV 
pGlucaon BQGTFTSDXSKYLDSRRAQDFVQWLMNT 
pGIP YAEGT~ISD~SIAMDKIRQQDFV~WL~AQKGKKSDWKHNITQ 
0 Somatostatin AGCKNFFWKT~SC 
Amino acids in identical positions are underlined: A, alanine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G,
glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; Q, glutamine; R, a&nine; S, 
serine; T, threonine; V, valine; W, tryptophane; Y, tyrosine; p: porcine; hp: human pancreatic; o: ovine 
(I&= 17 x lOa M). In agreement with these 
results, VIP, PHI, hpGRF and secretin were able 
to inhibit ?-VIP binding to plasma membranes 
prepared from human fetal enterocytes (fig. 4, 
right). VIP at a concentration of 5 x 10-i’ M 
halved the initial binding (13 pmol ‘251-VIP/mg 
membrane protein), whereas with the highest pep- 
tide concentrations tested, binding was reduced by 
9% (lo-’ M PHI), 73% (4x 10m6 M hpGRF) or 
26% (10e6 M secretin). 
4. DISCUSSION 
We report here the presence of functional and 
specific receptors for VIP in enterocytes isolated 
from human fetuses at 18-23 weeks gestational 
age. The specificity of the receptors was deter- 
mined by the use of peptides structurally related or 
unrelated to the VIP family (table 2). The relative 
potencies of these peptides for adenylate cyclase 
activation or ‘*‘I-VIP binding (VIP > PHI > 
GRF > secretin) characterized the VIP recognition 
sites, since the same sequence was previously 
established in different tissues known to contain 
VIP receptors [7,9,10,17-221. Such interactions of 
PHI, GRF and secretin with VIP receptors are due 
to the importance of the N-terminal region of the 
VIP molecule for its biological activity [23,24]. 
These four peptides possess 4-5 identical amino 
acid residues between positions 1 and 7 at their N- 
terminal end (table 2). In contrast, pancreatic 
glucagon, GIP, somatostatin-14 and other pep- 
tides or effecters unrelated to VIP were found here 
to be inactive in the adenylate cyclase system. 
Thus, the relative and absolute pharmacological 
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specificity of the VIP receptor in human entero- 
cytes are established at an early stage of fetal life 
and remain constant during development. Similar- 
ly, the activity and regulatory properties of the en- 
zymes forming or degrading cyclic AMP were 
characterized in the present preparation. We also 
examined agents [25] that activate adenylate 
cyclase directly, via the catalytic subunit C (sodium 
fluoride, forskolin) or by interacting with the 
CTP-dependent regulatory complex Ni as well 
(forskolin). 
Comparison of the potency of VIP in inhibiting 
i2’I-VIP binding and activating adenylate cyclase 
in human fetal enterocytes on the one hand and 
adult enterocytes on the other must be interpreted 
with caution, because of the differences in ex- 
perimental conditions. For instance, in adults 
[ 19,201, experiments were performed on intact col- 
onic crypts (to test ?-VIP binding) or on dif- 
ferent membrane preparations and reaction mix- 
ture, to test adenylate cyclase activity. Never- 
theless, it was observed here that for both these 
parameters VIP was about 4 times more,potent in 
fetal than in adult enterocytes in man. In agree- 
ment with this observation we recently demonstrat- 
ed [26] that rat fetal enterocytes at 19 days gesta- 
tion are about 6 times more sensitive to VIP (EC50 
= 2.5 x lo-” M VIP) than adult rat enterocytes 
(,!?CTO = 15 x lo-” M). Similarly, Laburthe et al. 
[20,27] have shown that human colonic HT-29 car- 
cinoma cells are 4 times more sensitive to VIP 
(EC5o = 3 x lo-*’ M) than colonic epithelial cells 
isolated from normal human colon (EC50 = 12 x 
lo-” M). 
This study provides the first example of VIP 
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receptor activity (determined by “‘I-VIP binding 
and adenylate cyclase activation) in human fetal 
tissue. The receptor-cyclic AMP system sensitive to 
VIP was functionally similar in fetal enterocytes 
and adult human intestine as regards pharmacol- 
ogical specificity, 1251-VIP binding capacity, cyclic 
AMP-phosphodiesterase activity, and expression 
of the C and Ni components of adenylate cyclase, 
and perhaps more sensitive to VIP. These results 
confirm and extend those previously reported from 
this laboratory [26,28,29] indicating that specific 
receptors for the regulatory peptides of the VIP- 
secretin family are functional in the gastrointes- 
tinal mucosa during fetal life. In the human small 
intestine and duodenum, villi, crypts and special- 
ized cell types appear at 9-12 weeks of gestation 
[14]. The outgrowth of villi in the duodenum at 8 
weeks coincides with the maturation of the brush 
border enzymes sucrase, lactase and aminopepti- 
dase in the small intestine [30]. If these results are 
considered together with previous histochemical 
and biochemical demonstrations of VIP immuno- 
reactivity in nerve fibers at 12 weeks of fetal age 
[11,12], and with the early cellular differentiation 
and enzymatic maturation of the small intestinal 
mucosa [14,30], they indicate that VIP might have 
a direct effect on human fetal enterocytes and 
might also modulate their biological activities 
(metabolism, differentiation and function) from 
the fetal age in man. Studies are now in progress 
on cultured normal and cancerous intestinal cells 
in an attempt to confirm this hypothesis. 
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